Ivabradina Genepharm

Active Ingredient:: Ivabradine Hydrochloride
Origin:: EU

Ivabradina Genepharm (Ivabradine Hydrochloride)

Q: Who should not use Ivabradina Genepharm?

Ivabradina Genepharm is contraindicated in patients with severe sinus bradycardia (resting heart rate <50 bpm), sick sinus syndrome, acute decompensated heart failure, uncontrolled hypotension, or in those taking strong CYP3A4 inhibitors without dose adjustment. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Ivabradine, the active ingredient in Ivabradina Genepharm, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate without affecting contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradina Genepharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Manufacturer / TM Owner

Genepharm S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradina Genepharm acts on the cardiac If current to manage conditions characterized by excessive heart rate.

Chronic stable angina: reduces frequency of angina attacks by lowering heart rate.
Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalizations.
Coronary artery disease: helps control heart rate and relieve ischemic symptoms.

How It Works

Ivabradine selectively binds to the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the funny (If) current in sinoatrial node cells. By inhibiting this inward Na⁺/K⁺ current, the drug slows spontaneous depolarisation, leading to a reduction in heart rate while myocardial contractility and ventricular repolarisation remain unchanged. The effect is dose‑dependent and reversible, allowing precise titration of heart rate without affecting blood pressure.

Side Effects

Ivabradina Genepharm may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

Visual disturbances (phosphenes): transient luminous phenomena.
Bradycardia: heart rate below 50 beats per minute.
Headache: mild to moderate intensity.
Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

Severe bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Hepatic enzyme elevation.

Precautions & Warnings

Before prescribing Ivabradina Genepharm, clinicians should consider several precautionary measures to ensure patient safety.

Cardiac monitoring: assess resting heart rate and ECG before initiating therapy.
Concomitant beta‑blockers: avoid combined use unless closely supervised to prevent excessive bradycardia.
Severe hepatic impairment: use with caution or avoid, as drug clearance may be reduced.
Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk.
Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Avoid Interactions

Ivabradina Genepharm can interact with other medicines that affect its metabolism or heart rate.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure.
Other heart‑rate‑lowering agents (beta‑blockers, digoxin): may cause severe bradycardia.
CYP3A4 inducers (e.g., rifampicin): may reduce ivabradine efficacy.

Moderate Interactions (Monitor Closely)

Calcium channel blockers (verapamil, diltiazem): may raise plasma levels modestly.
Antihypertensives: may enhance hypotensive effect.

Frequently Asked Questions

Ivabradina Genepharm contains ivabradine, which is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By reducing the heart rate, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node by binding to HCN channels. This inhibition slows the spontaneous depolarisation of pacemaker cells, resulting in a lower heart rate while preserving myocardial contractility and blood pressure.

The dose of Ivabradina Genepharm is individualized. A qualified prescriber determines the appropriate strength and titration schedule based on the patient’s resting heart rate, clinical response, and tolerance, following local prescribing guidelines.

Safety data for ivabradine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for heart‑rate reduction is beta‑blockers. Unlike beta‑blockers, ivabradine lowers heart rate without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or insufficient. However, ivabradine does not provide the anti‑ischemic or anti‑arrhythmic benefits that some beta‑blockers offer.

Ivabradina Genepharm should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed throughout storage.

The medication is supplied as oral tablets that are swallowed whole with water. It can be taken with or without food, and the dosing interval is usually once daily, although the exact schedule is set by the prescribing clinician.

The most serious adverse events include severe bradycardia (heart rate <50 bpm), atrial fibrillation or other significant arrhythmias, and rare visual disturbances that may progress to persistent visual loss. Prompt medical attention is required if any of these symptoms occur.

Ivabradina Genepharm is contraindicated in patients with severe sinus bradycardia (resting heart rate <50 bpm), sick sinus syndrome, acute decompensated heart failure, uncontrolled hypotension, or in those taking strong CYP3A4 inhibitors without dose adjustment. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.